BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22993347)

  • 1. Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma.
    Mitselou A; Skoufi U; Tsimogiannis KE; Briasoulis E; Vougiouklakis T; Arvanitis D; Ioachim E
    Anticancer Res; 2012 Sep; 32(9):3977-85. PubMed ID: 22993347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
    Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidine phosphorylase expression in patients with colorectal cancer and its association with angiogenesis-related proteins and extracellular matrix components.
    Mitselou A; Ioachim E; Skoufi U; Tsironis C; Tsimogiannis KE; Skoufi C; Vougiouklakis T; Briasoulis E
    In Vivo; 2012; 26(6):1057-67. PubMed ID: 23160694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.
    Ioachim E; Michael MC; Salmas M; Damala K; Tsanou E; Michael MM; Malamou-Mitsi V; Stavropoulos NE
    BMC Cancer; 2006 May; 6():140. PubMed ID: 16732887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
    BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.
    Ioachim E; Damala K; Tsanou E; Briasoulis E; Papadiotis E; Mitselou A; Charhanti A; Doukas M; Lampri L; Arvanitis DL
    Histol Histopathol; 2012 Feb; 27(2):209-16. PubMed ID: 22207555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma.
    Peretti T; Waisberg J; Mader AM; de Matos LL; da Costa RB; Conceição GM; Lopes AC; Nader HB; Pinhal MA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):756-65. PubMed ID: 18617780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal matrix protein expression following preoperative systemic therapy in breast cancer.
    Tokes AM; Szasz AM; Farkas A; Toth AI; Dank M; Harsanyi L; Molnar BA; Molnar IA; Laszlo Z; Rusz Z; Kulka J
    Clin Cancer Res; 2009 Jan; 15(2):731-9. PubMed ID: 19147781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
    Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
    Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenascin-C expression and its prognostic significance in colorectal cancer.
    Lundin M; Nordling S; Lundin J; Haglund C
    Oncology; 2007; 72(5-6):403-9. PubMed ID: 18196927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of extracellular matrix proteins in ovarian serous tumors.
    Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
    Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
    Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors.
    Zheng H; Tsuneyama K; Cheng C; Takahashi H; Cui Z; Murai Y; Nomoto K; Takano Y
    Anticancer Res; 2007; 27(1A):259-65. PubMed ID: 17352241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-1 and tenascin expression in cystic tumors of the pancreas.
    Kylänpää L; Hagström J; Lepistö A; Linjama T; Kärkkäinen P; Kiviluoto T; Haglund C
    JOP; 2009 Jul; 10(4):378-82. PubMed ID: 19581738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
    Hu WG; Li JW; Feng B; Beveridge M; Yue F; Lu AG; Ma JJ; Wang ML; Guo Y; Jin XL; Zheng MH
    Eur Surg Res; 2007; 39(4):229-38. PubMed ID: 17446709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.
    Yoshimura H; Dhar DK; Kohno H; Kubota H; Fujii T; Ueda S; Kinugasa S; Tachibana M; Nagasue N
    Clin Cancer Res; 2004 Dec; 10(24):8554-60. PubMed ID: 15623639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
    Fujiya M; Watari J; Ashida T; Honda M; Tanabe H; Fujiki T; Saitoh Y; Kohgo Y
    Jpn J Cancer Res; 2001 Oct; 92(10):1074-81. PubMed ID: 11676858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
    Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
    Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.